Who Owns TScan Therapeutics Stock?
NASDAQ: TCRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 67.88%
- Held by insiders
- 1.76%
- Institutional holders
- 77
- Institutions 67.9%
- Insiders 1.8%
- Public and other 30.4%
Who owns TScan Therapeutics stock?
Institutional investors own about 67.9% of TScan Therapeutics's shares, spread across 77 institutions that file 13F reports. That level of institutional ownership is moderate. Insiders, including executives, directors and large founding shareholders, hold 1.76% of TCRX.
The largest institutional holders are Lynx1 Capital Management Lp (12.63%), BVF Inc. (8.76%) and Baker Bros. Advisors, LP (4.39%). Together, the top 10 institutions control 41.8% of shares outstanding. In their latest filings, 4 of the top 10 institutions increased their TCRX positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of TCRX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Lynx1 Capital Management Lp | 8.02M | 12.63% | 0.0% |
| BVF Inc. | 5.56M | 8.76% | 0.0% |
| Baker Bros. Advisors, LP | 2.78M | 4.39% | 0.0% |
| Vanguard Capital Management LLC | 2.16M | 3.40% | +0.2% |
| Two Sigma Investments, LP | 1.95M | 3.07% | +61.3% |
| Renaissance Technologies, LLC | 1.33M | 2.09% | -2.8% |
| Acadian Asset Management. LLC | 1.31M | 2.06% | +546.5% |
| Deer Management Co. LLC | 1.25M | 1.96% | 0.0% |
| Millennium Management Llc | 1.16M | 1.83% | -20.3% |
| Jacobs Levy Equity Management, Inc. | 1.05M | 1.65% | +29.9% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of TCRX
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.50M | 2.36% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 575.57K | 0.91% |
| BlackRock Health Sciences Term Trust | 405.90K | 0.64% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 299.65K | 0.47% |
| iShares Trust-iShares Micro-Cap ETF | 166.43K | 0.26% |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 87.57K | 0.14% |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 72.91K | 0.11% |
| Columbia Fd.s Series TRT I-Multi-Manager Small Cap Eqy. Strategies Fd. | 69.49K | 0.11% |
| Guidestone Funds-SMALL CAP EQUITY FUND | 65.81K | 0.10% |
| Nationwide Varbl Insurance TRT-NVIT Multi-Manager Small Company Fd. | 44.50K | 0.07% |
Frequently asked questions
Who is the largest shareholder of TScan Therapeutics?
Lynx1 Capital Management Lp is the largest institutional shareholder of TCRX, owning 12.63% of shares outstanding (8.02M shares) as of its latest 13F filing.
What percentage of TScan Therapeutics is owned by institutions?
Institutions own about 67.9% of TCRX shares and 69.1% of the public float.
How much of TScan Therapeutics do insiders own?
Insiders, such as officers and directors, own about 1.76% of TCRX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.